Summary & Overview
HCPCS Q4122: Dermacell acellular dermal matrix graft, per cm
HCPCS Level II code Q4122 denotes Dermacell products — Dermacell, Dermacell AWM, or Dermacell AWM porous — billed per square centimeter as an add-on supply in addition to a primary surgical procedure. The code captures use of an acellular dermal matrix graft commonly used in reconstructive and soft-tissue repair surgeries, where the product is supplied and billed separately from the primary operative code. Nationally, such add-on supply codes matter for consistent facility and professional billing, cost accounting for biologic implants, and policy alignment across commercial payers and Medicare.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code’s clinical context, typical sites of service, and the role of add-on biologic graft coding in reimbursement workflows. The publication outlines standard benchmarks and reporting elements relevant to hospital and ambulatory surgical billing, summarizes common modifier usage where applicable, and highlights policy and coverage considerations that typically affect payment determinations. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code Q4122 describes Dermacell, Dermacell AWM or Dermacell AWM porous, billed per square centimeter as an add-on product to be listed separately in addition to a primary procedure. This code represents an acellular dermal matrix graft product used in surgical reconstruction and tissue repair.
Service type: Acellular dermal matrix grafting / biologic implant product
Typical site of service: Hospital operating room, ambulatory surgical center, or outpatient surgical clinic, where implantable biologic grafts are used in reconstructive procedures.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with a full-thickness skin defect or chronic non-healing wound (for example, a large traumatic soft-tissue loss, post-oncologic excision defect, or a chronic diabetic foot ulcer) requiring placement of an acellular dermal matrix graft. The procedure uses Q4122 Dermacell (porous) as an add-on billed per square centimeter in conjunction with a primary wound reconstruction or coverage procedure. Workflow: preoperative assessment in clinic with wound measurement and debridement planning; operative debridement and preparation of the wound bed under appropriate anesthesia in an operating room or procedure suite; application of the Dermacell allograft sized to wound dimensions and secured to surrounding tissue; adjunctive measures such as negative-pressure wound therapy or split-thickness skin grafting may be performed during the same operative session; postoperative documented dressing changes, wound checks, and rehabilitation. Typical sites of service include the hospital operating room, ambulatory surgery center, or hospital outpatient department, depending on complexity and patient comorbidities. Common clinical reasons for use include reconstruction after skin cancer excision, coverage of exposed tendon or bone, and management of complex infected or ischemic wounds where durable soft-tissue coverage is required.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services |